Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of obinutuzumab monotherapy in rituximab-refractory follicular lymphoma
2013-004635-69Phase 2Completed
- Sponsor
- VU University Medical Center
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in follicular lymphoma (FL), sponsored by VU University Medical Center. Started Mar 2014; status: completed.
02
Drugs
obinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2013-004635-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004635-69.